NCT01784913

A Phase I/IIa Study of UV1 Vaccine in Patients With Prostate Cancer

A Phase I/IIA Study of UV1 Vaccination in Patients With Hormone-sensitive Metastatic Prostate Cancer

• Status: Completed
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 22 (actual)
• Sponsor: Ultimovacs ASA · Industry
• Sex: Male
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

In this study, up to 21 patients with metastatic prostate cancer will receive UV1 (a therapeutic synthetic peptide vaccine) at different dose levels. The safety and tolerability of UV1 as well as immunological response will be assessed. The purpose of this study is to select a biological dose of peptides for further clinical trials. Main treatment period is completed and reported. Follow-up ongoing.

Detailed description

The study is an open labeled dose-escalating phase I/IIa study of UV1 peptide vaccination in patients with androgen-sensitive metastatic prostate cancer. Patients will be prospectively enrolled in this study if diagnosis of adenocarcinoma only has been histologically confirmed and they are eligible for (or have already started up to 6 months prior to inclusion) standard GnRH-agonist first line androgen deprivation therapy (ADT) combined with anti-androgen to achieve complete androgen blockade (CAB). UV1 vaccinations will be applied simultaneously with CAB. When indicated, patients may receive concomitant radiotherapy. The following 2-step design will be used: 1. Conventional dose escalation with at least 3 patients per dose level (3 selected dose levels). 2. Expansion of each dose level to a total of 7 patients for assessment of immune response levels 13 UV1 vaccinations will be given during the first 6 months (week 26) of treatment, unless clinical deterioration or unacceptable toxicity is encountered. GM-CSF (Leukine ®) will be administered locally 10-15 minutes before each UV1 vaccination. Hormone naïve patients will receive standard complete androgen blockade by GnRH-agonist (3 months depot formulation sc.) and bicalutamide 50 mg orally per day (CAB). Patients already on GnRH-agonist therapy will continue with their initial treatment with addition of bicalutamide 50 mg orally per day.

Conditions

• Prostate Cancer

Interventions

Type	Name	Description
BIOLOGICAL	UV1 synthetic peptide vaccine and GM-CSF

Timeline

• Start date: 2013-04-15
• Primary completion: 2015-07-08
• Completion: 2020-10-23
• First posted: 2013-02-06
• Last updated: 2024-12-16

Locations

1 site across 1 country: Norway